Gene Therapy on Cardiovascular Disease Market Size is predicted to grow at a 67.4% CAGR during the forecast period for 2024-2031.
Gene therapy for cardiovascular disease shows promising potential but is primarily in the experimental and clinical trial stages. Achievement in this domain has the potential to result in groundbreaking therapies for conditions that presently possess restricted therapeutic alternatives. One approach to gene therapy that makes use of viral vectors is the delivery of therapeutic genes to cells in the cardiovascular system. Gene therapy for cardiovascular illness is seeing increased demand for a variety of reasons. As a primary cause of mortality globally, cardiovascular disease has an urgent need for improved treatment options.
Further, advancements in gene delivery technology and genetic engineering have made it feasible to create and deliver therapeutic genes more safely and efficiently. The rising incidence of long-term diseases, including cancer, rare genetic disorders affecting a wide range of uncommon diseases, and others, is a major force propelling the gene therapy market forward. Several factors, including rising cancer rates, ethical acceptance of gene therapy as a cancer treatment, and more government support, drive market expansion.
However, the market growth is hampered by the high-cost criteria for the safety and health of gene therapy in the cardiovascular disease market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high low code technology in insurance, because of the lack of payment criteria and adequate insurance coverage, the therapeutic procedures have become prohibitively expensive. Coverage of gene therapies, especially for uncommon diseases or syndromes, may be hesitant by insurance companies and healthcare providers because of the lack of data on the long-term safety and effectiveness of these treatments. The total expansion of the gene therapy market for cardiovascular illness may be hindered, and patients may find it difficult to receive these medicines. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories in an effort to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
Gene therapy in the cardiovascular disease market is segmented based on type and application. As per the type, the market is segmented into viral gene therapy and non-viral gene therapy. By application, the market is segmented into heart disease and vascular disease.
Viral gene therapy in the cardiovascular disease market is expected to lead with a major global market share in 2023. The use of viral vectors to treat hereditary diseases like muscular dystrophy and cystic fibrosis is very promising. They pave the door for better patient outcomes by delivering functional genes that attenuate genetic mutations.
Vascular disease makes up the bulk of acrylic acid ester usage because it impacts the blood vessels or circulatory system. From circulatory illnesses to those affecting the arteries, veins, and lymph vessels, this covers almost everything, especially in countries like the US, Germany, the U.K., China, and India.
The North American gene therapy in the cardiovascular disease market is expected to record a large market revenue share in the near future. It can be attributed to the prevalence of chronic diseases, high and rising healthcare expenditure, an advanced healthcare infrastructure, available reimbursements, and the presence of major market players. In addition, Europe is predicted to grow rapidly in the global gene therapy in cardiovascular disease market due to the huge amount of registered clinical trials linked to the treatments. The significant focus on government funding and reforms is another factor expected to contribute to expanding the region's chimeric antigen gene therapy market in the coming years.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 67.4 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type And Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics and other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy on Cardiovascular Disease Market Snapshot
Chapter 4. Global Gene Therapy on Cardiovascular Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Viral Gene Therapy
5.2.2. Non-Viral Gene Therapy
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Heart Disease
6.2.2. Vascular Disease
Chapter 7. Gene Therapy on Cardiovascular Disease Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.1.2. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.1.3. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.2.2. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.2.3. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.3.2. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.3.3. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.4.2. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.4.3. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.5.2. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.5.3. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Biogen
8.2.2. Novartis
8.2.3. Gilead Sciences
8.2.4. Sarepta Therapeutics
8.2.5. Alnylam Pharmaceuticals
8.2.6. Amgen
8.2.7. Spark Therapeutics
8.2.8. Akcea Therapeutics
8.2.9. Sunway Biotech
8.2.10. bluebird bio
8.2.11. SIBIONO
8.2.12. AnGes
8.2.13. Orchard Therapeutics
8.2.14. Other Market Players
Gene Therapy on Cardiovascular Disease Market By Type-
Gene Therapy on Cardiovascular Disease Market By Application-
Gene Therapy on Cardiovascular Disease Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
